Forecast for Vaccine Stocks After Coronavirus Pandemic Passes
Stephen Gardner, director at ETF Managers Group, explains why investors shouldn't be rushing to sell vaccine stocks like Moderna or BioNTech even as the spread of COVID-19 slows down.
Aurimas Sabulis, CEO of Dextall, unveils how AI‑driven prefabricated façades slash design time by 80%, labor by 87%, and accelerate affordable housing delivery.